Warren Center For Neuroscience Drug Discovery

Vanderbilt University has signed an exclusive worldwide license and research collaboration agreement with Neumora Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience. Read More

Stressful events can rapidly modify how the brain responds to its environment and guides behaviors. These processes are relevant for neurotypical brain function and for the development of affective disorders and other psychiatric diseases, yet we have much to learn regarding the underlying molecular mechanisms. In this paper, researchers utilized pharmacologic, transgenic, and optogenetic tools to evaluate changes in brain function related to stress. Read More

Ege T. Kavalali, William Stokes Professor of Experimental Therapeutics, has been named chair of the Department of Pharmacology in the Vanderbilt University School of Medicine Basic Sciences. Read More

Appello Pharmaceuticals Inc. begins trial of a drug candidate that improves relief from symptoms of Parkinson’s disease without debilitating side effects. Read More

Jeffrey Conn, Lee E. Limbird Chair and professor of pharmacology, is among 16 scientists named 2021 fellows of the American Society for Pharmacology and Experimental Therapeutics. Selection as a fellow of ASPET is an honor bestowed on members who have demonstrated excellence in their efforts to advance pharmacology through scientific achievements, mentorship and service to the society. Read More

Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and director of Vanderbilt’s  Warren Center for Neuroscience Drug Discovery, will be inducted to the 2021 class of the Division of Medicinal Chemistry Hall of Fame. Read More

A new partnership between Vanderbilt University’s Warren Center for Neuroscience Drug Discovery and clinical stage biopharmaceutical company Soleno Therapeutics will further research into new clinical treatments for multiple obesity syndromes. Read More

Behavioral and systems neuropharmacologist Jerri Rook is recognized by the Alzheimer’s Drug Discovery Foundation with the Goodes Prize to continue her work in Alzheimer’s disease research. Read More

Craig Lindsley, the William K. Warren, Jr. Chair and University Professor of Pharmacology, Biochemistry and Chemistry, will become director of Vanderbilt University’s Warren Center for Neuroscience Drug Discovery, effective Dec. 1, 2020. Read More

The VBI recently marked its 20th anniversary, a span that has seen the institute’s wide-ranging missions—including administering the university’s Neuroscience Graduate Program, as well as postdoctoral training and community outreach—steadily coalesce under a single umbrella. Read More

VU319, an investigational drug product developed by Vanderbilt researchers, targets one of medicine’s most bedeviling challenges: improving memory loss in people with Alzheimer’s disease. Read More

Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia. Read More

Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science." Read More

Vanderbilt University has received $20 million from The William K. Warren Foundation, located in Tulsa, Oklahoma, to establish the Warren Center for Neuroscience Drug Discovery to support pharmaceutical breakthroughs. Read More